Klimek Ludger, Bachmann Martin F, Senti Gabriela, Kündig Thomas M
Center for Rhinology and Allergology, An den Quellen 10, D-65183 Wiesbaden, Germany.
Expert Rev Clin Immunol. 2014 Aug;10(8):1059-67. doi: 10.1586/1744666X.2014.924854. Epub 2014 Jun 5.
Immunotherapy of type-I-allergies is regarded as the most efficient treatment option besides allergen avoidance. Different forms of allergen preparations are used as well as different routes of application. Virus-like particles represent a potent vaccine platform with proven immunogenicity and clinical efficacy. The addition of toll-like receptor ligands and/or depot-forming adjuvants further enhances immune cell activation. This article will focus on the function of virus-like particles loaded with DNA rich in CpG-motifs and discuss clinical experience in treatment of allergic rhinitis. Evidence will be presented that clinically effective treatment can be obtained even in the absence of allergens. Results encourage further investigation of virus-like particles and CpG-motifs in immunotherapy, either as a stand alone product, or as adjuvants for allergen-specific immunotherapy.
除了避免接触过敏原外，I型过敏的免疫疗法被认为是最有效的治疗选择。人们使用了不同形式的过敏原制剂以及不同的给药途径。病毒样颗粒是一种有效的疫苗平台，具有已证实的免疫原性和临床疗效。添加Toll样受体配体和/或形成储存库的佐剂可进一步增强免疫细胞的激活。本文将重点关注负载富含CpG基序的DNA的病毒样颗粒的功能，并讨论治疗过敏性鼻炎的临床经验。将提供证据表明，即使在没有过敏原的情况下也能获得临床有效的治疗。这些结果鼓励进一步研究病毒样颗粒和CpG基序在免疫疗法中的应用，无论是作为单一产品，还是作为过敏原特异性免疫疗法的佐剂。
